PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
Airway mucus hypersecretion (AMH) is a key pathophysiological feature of chronic airway inflammatory diseases such as bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway inflammatory diseases, and it is associated with r...
Saved in:
Main Authors: | Yongchun Shen, Lei Chen, Tao Wang, Fuqiang Wen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2012/256874 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial Cells
by: Takeshi Shimizu, et al.
Published: (2012-01-01) -
Chitooligosaccharides suppress airway inflammation, fibrosis, and mucus hypersecretion in a house dust mite-induced allergy model
by: Yun-Ho Kim, et al.
Published: (2025-01-01) -
PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy
by: Chantal Donovan, et al.
Published: (2012-01-01) -
Hyperresponsiveness in the Human Nasal Airway: New Targets for the Treatment of Allergic Airway Disease
by: P. J. Turner, et al.
Published: (1999-01-01) -
PPARγ in Inflammatory Bowel Disease
by: Vito Annese, et al.
Published: (2012-01-01)